Prosight Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-45,000
| Closed | -$4.18M | – | 41 |
|
|
2021
Q4 | $4.18M | Sell |
45,000
-108,400
| -71% | -$7.14M | 2.5% | 15 |
|
|
2021
Q3 | $9.13M | Buy |
153,400
+16,400
| +12% | +$969K | 5.03% | 5 |
|
|
2021
Q2 | $9.34M | Buy |
137,000
+31,172
| +29% | +$2.03M | 5.84% | 3 |
|
|
2021
Q1 | $7.34M | Sell |
105,828
-39,872
| -27% | -$3.07M | 6.01% | 4 |
|
|
2020
Q4 | $11.2M | Sell |
145,700
-17,357
| -11% | -$1.3M | 5.17% | 5 |
|
|
2020
Q3 | $12.2M | Sell |
163,057
-64,155
| -28% | -$4.28M | 5.8% | 2 |
|
|
2020
Q2 | $14.3M | Sell |
227,212
-192,390
| -46% | -$10.6M | 6.14% | 2 |
|
|
2020
Q1 | $17.6M | Buy |
419,602
+91,473
| +28% | +$4.19M | 8.24% | 1 |
|
|
2019
Q4 | $14.9M | Buy |
328,129
+164,996
| +101% | +$7.8M | 6.54% | 3 |
|
|
2019
Q3 | $7.47M | Sell |
163,133
-1,167
| -0.7% | -$65.6K | 4.14% | 8 |
|
|
2019
Q2 | $9.63M | Sell |
164,300
-88,200
| -35% | -$4.56M | 4.86% | 6 |
|
|
2019
Q1 | $11.3M | Sell |
252,500
-25,150
| -9% | -$1.15M | 4.95% | 6 |
|
|
2018
Q4 | $10.8M | Buy |
277,650
+33,600
| +14% | +$1.32M | 5.58% | 5 |
|
|
2018
Q3 | $11.2M | Buy |
244,050
+104,522
| +75% | +$4.24M | 6.26% | 3 |
|
|
2018
Q2 | $6.08M | Buy |
139,528
+19,128
| +16% | +$822K | 4.46% | 7 |
|
|
2018
Q1 | $4.76M | Buy |
+120,400
| New | +$4.68M | 2.98% | 14 |
|
Prosight Management's ARNA Position: Q1 2022 in Review
Prosight Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 45,000 shares — an estimated $4.18M sold.
Prosight Management first reported a position in ARNA in Q1 2018 and held it in 16 quarters. The position peaked at $17.6M in Q1 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Prosight Management reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Prosight Management sold 45,000 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $4.18M.
- Prosight Management first reported a position in Arena Pharmaceuticals Inc in Q1 2018 and held it in 16 quarters.
- Prosight Management's Arena Pharmaceuticals Inc position peaked at $17.6M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Prosight Management's 13F filing for Q1 2022, filed 16 May 2022.